Latest CGMP specific phosphodiesterase type 5 Stories
redOrbit Staff & Wire Reports - Your Universe Online Taking a popular type of erectile dysfunction drug will not help patients suffering from a specific type of heart failure from increasing the maximum amount of physical exertion that they can withstand, according to a new study published Monday in the online edition of JAMA. The results of the (RELAX) study, determined that individuals who have heart failure with preserved ejection fraction (HFPEF) – a condition in which the...
INDIANAPOLIS, Sept. 21, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of Cialis® (tadalafil) tablets 5 mg for once a day use for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). The CHMP's opinion is now referred to the European Commission, which has the authority to approve...
GREENWOOD VILLAGE, Colo., July 2, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) & Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that it is proceeding with the development plan for a combination product to treat both premature ejaculation (PE) and erectile dysfunction (ED). The positive pre-IND meeting...
FARMINGTON, Conn., June 25, 2012 /PRNewswire-iReach/ -- The enzyme inhibitors industry in emerging markets has significant potential, in contrast to mature markets where growth is significantly slower. Having accurate market data and analysis is essential to companies that wish to compete on the global stage. With premium market research from the world's leading publishers, Global Information Inc. helps businesses stay on the cutting edge with the best forecasts, research, and...
Echo study at the Children's Hospital of Philadelphia shows improvements in children, young adults with single ventricle Sildenafil, also known as the erectile dysfunction drug Viagra, may give a boost to underdeveloped hearts in children and young adults with congenital heart defects. Researchers from The Children's Hospital of Philadelphia report that sildenafil significantly improved echocardiographic measures of heart function in children and young adult survivors of single ventricle...
MOUNTAIN VIEW, Calif., April 27, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment of erectile dysfunction (ED), marking the first new prescription agent approved in nearly a decade for the condition that afflicts as many as 30 million men in the U.S. "Patients and treating physicians continue to report significant dissatisfaction with current treatments of...
GREENWOOD VILLAGE, Colo., Jan. 17, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced notification by the European Patent Office they will be awarded two new patents in Europe for the combination of Zertane(TM) (Ampio's premature ejaculation (PE) drug) with any erectile dysfunction (ED) drug of the PDE5...
MOUNTAIN VIEW, Calif., Dec. 5, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented over the weekend at the 2011 European Society of Sexual Medicine (ESSM) Meeting in Milan, Italy. The ESSM is the largest gathering of medical professionals specializing in sexual dysfunction and treatment in Europe. The specific abstracts that were presented on December 3rd, 2011 include: A moderated poster presentation by...
MOUNTAIN VIEW, Calif., Nov. 10, 2011 /PRNewswire/ -- Highlights from Avanafil Development Program Include: Early onset of action observed in placebo-controlled trialsComparative in-vitro selectivity of avanafil, sildenafil, vardenafil and tadalafilSafety and efficacy in post-prostatectomy populationVIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at the Sexual Medicine Society of North America (SMSNA) on November 12, 2011 in Las Vegas, NV. The SMSNA is...
INDIANAPOLIS, Oct. 7, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Cialis® (tadalafil) tablets for once daily use for the treatment of men who have both erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED+BPH). The FDA also approved Cialis for once daily use for a separate indication for the treatment of the signs and symptoms of BPH. This means Cialis is now approved...
